 IRVINE, Calif.--BUSINESS WIRE--Axonics, Inc. Nasdaq: AXNX, a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval PMA supplement with the FDA for its newly developed, long-lived, non-rechargeable sacral neuromodulation SNM implantable neurostimulator INS. Axonics has designed its new non-rechargeable SNM system to replicate key features of its currently marketed, FDA-a 